El objeto que está siendo arrastrado hacia el centro galáctico
En este Short conoceremos el misterioso objeto X7. …
El objeto que está siendo arrastrado hacia el centro galáctico Read More »
Uncategorized
Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy
Aviceda Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 – March 20, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479.
Neurofilament as a Surrogate Endpoint Goes on Trial in Tofersen Adcomm
Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.
Neurofilament as a Surrogate Endpoint Goes on Trial in Tofersen Adcomm Read More »
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn’s Statements
Illumina today issued the following response to Carl Icahn’s public statements and letters to Illumina’s shareholders dated March 13 and March 15, 2023.
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labelled somatostatin analogue therapy.
Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases
Rubedo Life Sciences presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.
Dirk Bontridder Appointed as CEO of New PerkinElmer Business Acquired by New Mountain Capital
The new PerkinElmer business acquired by New Mountain Capital announced today the appointment of Dirk Bontridder as Chief Executive Officer effective March 13, 2023.
Synchron to Begin Patient Enrollment for the COMMAND Trial of Brain-Computer Interface at Gates Vascular Institute
Synchron today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB).
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo Read More »